Diagnosis & Disease Information

Low-dose-rate brachytherapy boost (LDR-PB) achieves better rates of biochemically disease-free outcomes in prostate cancer.

Variants of gene SLCO2B1 associated with progression and survival among patients undergoing androgen deprivation therapy (ADT) for prostate cancer.

Compared with prednisone, cabozantinib does not improve overall survival rates for men with metastatic castration-resistant prostate cancer (mCRPC).

Adding docetaxel to androgen deprivation therapy (ADT) does not improve overall survival in hormone-naïve metastatic prostate cancer.

Androgen receptor V7 (AR-V7) status does not predict response to taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).

Adding bicalutamide improves overall survival among patients with advanced nonmetastatic hormone-naïve prostate cancer.

The 4Kscore could dramatically reduce the number of unnecessary prostate biopsies.